$HIMS (-3,56 %)
Hims & Hers announces the following in its latest quarterly figures:
Talks with Novo Nordisk $NOVO B (+6,8 %)
$NVO (+7,05 %):
"Hims & Hers and Novo Nordisk are in active discussions to make Wegovy injections and Novo Nordisk's oral Wegovy (if approved by the FDA)
available through the Hims & Hers platform, thereby expanding options for consumers and [doing so] as recommended by the prescribing physician. Hims & Hers notes that discussions are ongoing, no definitive agreement has been signed with Novo Nordisk, and there is a possibility that a definitive agreement with Novo Nordisk may never be signed. In addition, if a definitive agreement is signed, these terms may differ from what is currently expected. Although Hims & Hers may voluntarily disclose the terms of a definitive agreement if and when it is signed, depending on the contours of such an agreement, Hims & Hers may not have a legal obligation to do so."
What happened on 23.06.2025:
Partnership between Novo Nordisk and Hims & Hers collapsed:
-The $HIMS (-3,56 %) The share loses over -30% in one day.
Novo Nordisk, the manufacturer of Wegovy, abruptly ended its collaboration with the telemedicine platform Hims & Hers (Hims), which only began in April, on Monday (June 23, 2025).
The two companies are making serious accusations against each other:
1. accusations by Novo Nordisk (manufacturer):
- Illegal copying: Novo accuses Hims of continuing to sell "compounded" (individually mixed) versions of semaglutide (the active ingredient in Wegovy).
- No more bottleneck: According to Novo, the sale of these copies was only allowed during the official drug shortage by the US FDA. However, this bottleneck has been officially declared over.
- Deceptive marketing: Novo accuses Hims of selling these copies en masse under the "false guise of personalization" and engaging in "deceptive marketing."
- Other partners are cooperative: Novo emphasized that partnerships with Hims competitors (such as LifeMD and Ro) remain in place because they have made efforts to switch patients to the original Wegovy.
2. allegations by Hims & Hers (platform):
- Attempted control: Hims CEO Andrew Dudum accuses Novo of trying to "strong-arm" the company.
- Patient control: Novo allegedly tried to control clinical standards at Hims in order to "steer" patients specifically to the more expensive original Wegovy.
- Anti-competitive: Hims describes these claims as "anti-competitive" and an interference with doctors' and patients' freedom of choice.
- Hims continues: Hims announced that it will continue to sell both the original Wegovy and other treatments (including the cheaper, fortified doses).
Due to the tense situation at Novo Nordisk, the company appears to be relenting and entering into renewed talks with Hims & Hers. Apparently there is a change of course by the new CEO and Novo Nordisk recognizes the importance of the Hims & Hers distribution channel. The previous fears of a lawsuit against Hims & Hers have also not materialized.
Coupled with the current good quarterly figures for Q3 2025, this could have a positive impact on $HIMS (-3,56 %) have. 🚀
